Drugs that contain Aripiprazole
1. List of Abilify drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 12 days ago) | |
| US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(1 year, 12 days ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(1 year, 12 days ago) | |
| US6977257 | OTSUKA | Aripiprazole oral solution |
Apr, 2022
(9 months ago) | |
|
US8642600
(Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(6 months ago) | |
|
US6977257
(Pediatric) | OTSUKA | Aripiprazole oral solution |
Oct, 2022
(3 months ago) | |
|
US8642760
(Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(a month from now) | |
|
US8580796
(Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(a month from now) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(10 months from now) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 4 months from now) | |
| US7550445 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(1 year, 5 months from now) | |
| US7115587 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(1 year, 5 months from now) | |
|
US8017615
(Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(1 year, 10 months from now) | |
|
US7115587
(Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(1 year, 11 months from now) | |
|
US7550445
(Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(1 year, 11 months from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(3 years from now) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(4 years from now) | |
Market Authorisation Date: 07 June, 2006
Treatment: Treatment of schizophrenia; Treatment of irritability associated with autistic disorder; Treatment of major depressive disorder (mdd); Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY family patents
68
United States
38
China
19
Hong Kong
14
European Union
13
Japan
13
Canada
12
Poland
12
Norway
10
Ukraine
10
Spain
10
Argentina
10
Portugal
10
Denmark
9
Cyprus
8
Austria
7
Korea, Republic of
7
Germany
7
Slovenia
7
Russia
7
Taiwan, Province of China
6
Israel
6
Georgia
5
Brazil
5
Australia
5
Malaysia
5
Mexico
5
South Africa
5
Peru
5
New Zealand
3
Hungary
3
Ecuador
2
Lithuania
2
Yugoslavia
2
Croatia
2
Iceland
1
Estonia
1
Chile
1
Uruguay
1
Slovakia
1
Colombia
1
Singapore
1
Bulgaria
1
Philippines
1
Czech Republic
2. List of Abilify Maintena Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8993761 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| US8399469 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089567 | OTSUKA PHARM CO LTD | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 12 days ago) | |
| US8759351 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(5 months from now) | |
| US8338428 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(5 months from now) | |
| US8030313 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 8 months from now) | |
| US7807680 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 8 months from now) | |
| US8722679 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 8 months from now) | |
| US8338427 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Mar, 2025
(2 years from now) | |
| US11400087 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US11344547 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US10980803 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US11154553 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(11 years from now) | |
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Maintenance monotherapy treatment of bipolar i disorder; Maintenance monotherapy treatment of bipolar 1 disorder
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT family patents
69
United States
31
China
16
Hong Kong
11
Japan
11
Norway
10
Poland
10
Canada
10
European Union
8
Spain
8
Portugal
8
Denmark
7
Austria
7
Ukraine
7
Cyprus
7
Slovenia
7
Argentina
6
Germany
4
Israel
4
Taiwan, Province of China
3
Korea, Republic of
3
Australia
3
Mexico
3
South Africa
3
Russia
3
Peru
3
Ecuador
2
Brazil
2
Malaysia
2
Georgia
2
New Zealand
1
Sweden
1
Chile
1
Lithuania
1
Luxembourg
1
Hungary
1
Colombia
1
Croatia
1
Philippines
3. List of Abilify Mycite Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 12 days ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(1 year, 12 days ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(10 months from now) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 4 months from now) | |
| US11476952 | OTSUKA | Pharma-informatics system |
Apr, 2026
(3 years from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(3 years from now) | |
| US7978064 | OTSUKA | Communication system with partial power source |
Sep, 2026
(3 years from now) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(4 years from now) | |
| US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(4 years from now) | |
| US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(5 years from now) | |
| US9258035 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(6 years from now) | |
| US9060708 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(6 years from now) | |
| US8674825 | OTSUKA | Pharma-informatics system |
Apr, 2029
(6 years from now) | |
| US8956288 | OTSUKA | In-body power source having high surface area electrode |
Jul, 2029
(6 years from now) | |
| US10441194 | OTSUKA | Ingestible event marker systems |
Jul, 2029
(6 years from now) | |
| US8945005 | OTSUKA | Controlled activation ingestible identifier |
Aug, 2029
(6 years from now) | |
| US9433371 | OTSUKA | In-body device with virtual dipole signal amplification |
Sep, 2029
(6 years from now) | |
| US8718193 | OTSUKA | Active signal processing personal health signal receivers |
Dec, 2029
(6 years from now) | |
| US9149577 | OTSUKA | Body-associated receiver and method |
Dec, 2029
(6 years from now) | |
| US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(7 years from now) | |
| US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(7 years from now) | |
| US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(7 years from now) | |
| US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(7 years from now) | |
| US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(7 years from now) | |
| US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(7 years from now) | |
| US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(7 years from now) | |
| US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(7 years from now) | |
| US11229378 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jul, 2031
(8 years from now) | |
| US9320455 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Dec, 2031
(8 years from now) | |
| US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(9 years from now) | |
| US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(10 years from now) | |
Market Authorisation Date: 13 November, 2017
Treatment: Treatment of schizophrenia; Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a receiver to receive a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver; Method of using a logic circuit to stabilize battery voltage supplied to a sensor embedded with a tablet and that communicates information via a signal through the body of a patient to a receiver
Dosage: TABLET;ORAL
ABILIFY MYCITE KIT family patents
219
United States
61
Japan
58
China
46
European Union
34
Canada
32
Israel
30
Hong Kong
26
Korea, Republic of
26
Taiwan, Province of China
18
Australia
18
Denmark
17
Spain
14
Brazil
14
Malaysia
14
Singapore
13
Ukraine
12
Mexico
12
Portugal
11
Poland
11
South Africa
11
Russia
10
Norway
8
Cyprus
7
Slovenia
7
Argentina
6
Austria
6
Germany
5
New Zealand
4
Georgia
4
Peru
4
India
4
Ecuador
3
Chile
2
Lithuania
2
Hungary
2
Philippines
1
Morocco
1
Finland
1
Tunisia
1
Colombia
1
EA
1
Costa Rica
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic